Therefore, we believe that this report provides compelling evidence that a VLP-based immunotherapy approach can be beneficial in preventing tau pathology and could be applicable to diverse human tauopathies, such as Alzheimer’s disease (AD), frontotemporal dementia (FTD), traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE). The gene discussed is MAPT; the disease is frontotemporal dementia.